Related Experiment Videos
New antipsychotic agents: emerging clinical profiles
1Northcoast Behavioral Healthcare System and Case Western Reserve University, Cleveland, Ohio 44106, USA.
The Journal of Clinical Psychiatry
|February 26, 1999
Summary
New antipsychotic medications offer improved schizophrenia treatment, requiring longer trials to assess efficacy across negative, cognitive, and rehabilitative symptoms. These advancements may reduce side effects and improve patient management.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Therapeutics
Background:
- The pharmacotherapy of schizophrenia has undergone significant evolution in the last five years.
- Several novel antipsychotic agents are now available, with more anticipated in the near future.
Purpose of the Study:
- To outline the evolving landscape of schizophrenia pharmacotherapy.
- To emphasize the need for updated clinical approaches to managing schizophrenia with new agents.
Main Methods:
- Review of recent advancements in antipsychotic pharmacotherapy for schizophrenia.
- Discussion of clinical trial methodologies and outcome measures for newer agents.
Main Results:
- New antipsychotics necessitate longer trials and broader outcome assessments (negative, cognitive, rehabilitative symptoms).
- Clozapine remains crucial for treatment-resistant schizophrenia; other new agents have wider indications.
- Efficacy of newer agents, especially in treatment-refractory cases, requires further determination.
Conclusions:
- The advent of new antipsychotics presents opportunities to decrease tardive dyskinesia and better manage comorbid substance abuse and aggression.
- More effective disease management through novel pharmacotherapy could lead to substantial cost savings.